Abstract
BackgroundThe ASAS criteria for peripheral spondyloarthritis (SpA) allow for classification of patients with SpA who present with peripheral arthritis, enthesitis and/or dactylitis.1 ABILITY-2, a placebo-controlled trial of adalimumab (ADA) for...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
